Use of MenACWY-CRM Vaccine in Children Aged 2 Through 23 Months at Increased Risk for Meningococcal Disease

Source: Morbidity and Mortality Weekly Report | Vol:Vol. 63 | Page: 527

By: MacNeil, Jessica R. ; Rubin, Lorry ; McNamara, Lucy


Infants aged two months to 23 months who are at increased risk for meningococcal disease may be able to receive a third meningococcal conjugate vaccine. This group includes infants with persistent complement component deficiencies, those with functional or anatomic asplenia, healthy infants who live in communities with a meningococcal disease outbreak that requires vaccination, and infants traveling to or living in areas where meningococcal disease is hyperendemic or epidemic. At its October 2013 meeting, the Advisory Committee on Immunization Practices recommended use of the vaccine MenACWY-CRM, the first quadrivalent meningococcal conjugate vaccine licensed for use in children aged two months to eight months. The burden of meningococcal disease in infants is low in the United States overall. Because most cases that do occur are caused by serogroup B, which is not included in any vaccine licensed in the United States, only those infants at increased risk for meningococcal disease may receive a meningococcal vaccine.

Copyright © 2014 Information, Inc.